http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2316340-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e29803d7579f2a913a4f39a8079e13c5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fce690e0fa27861015a75d3de54272bf |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-43 |
| filingDate | 2006-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2008-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f808955094cd9473850839827eba2e32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0368c4aa3adfe85beb90894e04934ae2 |
| publicationDate | 2008-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2316340-C1 |
| titleOfInvention | Method for treating pyo-inflammatory diseases in maxillofacial area |
| abstract | FIELD: medicine. n SUBSTANCE: method involves opening pyo-inflammatory focus. Rexod is introduced in addition to basic therapy. Rexod is introduced during the operation or immediately after the operation and then every day once a day intravenously in bolus dose. The drug is introduced during 4-5 days in physiologic saline or in 5% glucose solution at a dose of 0.2 mcg/kg of patient body weight. n EFFECT: enhanced effectiveness of treatment; improved general health state within a short period; reduced oxidation stress; prevented secondary active oxygen forms production. n 3 tbl |
| priorityDate | 2006-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 81.